Announcements Trials
Browse Landscape

Phase

Phase 2 203Phase 1 92Phase 3 39Phase 1/2 37Phase EARLY_PHASE1 9Phase 4 6Phase NA 3Phase 2/3 3

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 2Breast 1

Conditions

Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20Vincristine 18venetoclax 17apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × olaparib × Clear all
NCT05255653 2026-05-15

RAINBO

Leiden University Medical Center

Phase 2/3 Recruiting
1,615 enrolled
Gynecologic

Endometrial Neoplasms

NCT02502266 2026-04-29

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
582 enrolled 21 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03150576 2022-11-14

PARTNER

Cambridge University Hospitals NHS Foundation Trust

Phase 2/3 Recruiting
780 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡